Inspira Technologies Oxy BHN (IINN)
NASDAQ:IINN
Want to see IINN full AI Analyst Report?
Top Page
Inspira Technologies Oxy BHN
(NASDAQ:IINN)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.48
â–Ľ(-50.42% Downside)
Action:ReiteratedDate:03/28/26
The score is driven primarily by very weak financial performance (minimal/unstable revenue, sustained losses, and heavy cash burn) and bearish technical conditions (price below all key moving averages with negative MACD). Valuation provides limited support because the company is loss-making (negative P/E) and offers no dividend yield.
Positive Factors
Strategic AME acquisition expands capabilities
The Nano Dimension AME acquisition transfers IP, equipment and customer contracts, giving Inspira an in-house high-precision 3D electronics platform. This broadens addressable markets into quantum and advanced electronics, enables proprietary consumables and recurring revenue, and supports higher-margin industrial opportunities.
Negative Factors
Persistent negative operating and free cash flow
Operating and free cash flows are chronically negative, with annual cash burn in the mid‑single to low‑double millions and deterioration in 2025. Sustained cash burn necessitates external financing, elevates dilution risk, and limits investment in commercialization and R&D needed to scale businesses over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic AME acquisition expands capabilities
The Nano Dimension AME acquisition transfers IP, equipment and customer contracts, giving Inspira an in-house high-precision 3D electronics platform. This broadens addressable markets into quantum and advanced electronics, enables proprietary consumables and recurring revenue, and supports higher-margin industrial opportunities.
Read all positive factors
Inspira Technologies Oxy BHN (IINN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.14M
Dividend YieldN/A
Average Volume (3M)330.47K
Price to Earnings (P/E)―
Beta (1Y)2.09
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees37
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.21
Shares Outstanding43,579,260
10 Day Avg. Volume227,613
30 Day Avg. Volume330,466
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)11.48
Price to Sales (P/S)92.25
P/FCF Ratio-2.68
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue32.25
Enterprise Value/Gross Profit4.66K
Enterprise Value/Ebitda-1.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)$48.00M
Inspira Technologies Oxy BHN Business Overview & Revenue Model
Company Description
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the ...
How the Company Makes Money
null...
Inspira Technologies Oxy BHN Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
34
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 289.00K | 289.00K | 0.00 | 0.00 | -4.68M | 0.00 |
| Gross Profit | 2.00K | -272.00K | -488.00K | -406.00K | -5.04M | -218.00K |
| EBITDA | -7.16M | -13.16M | -11.10K | -10.87M | -14.68M | -16.72M |
| Net Income | -6.40M | -13.22M | -11.05K | -11.29M | -4.00M | -16.96M |
Balance Sheet | ||||||
| Total Assets | 4.45M | 5.34M | 8.07M | 9.31M | 16.01M | 25.87M |
| Cash, Cash Equivalents and Short-Term Investments | 2.13M | 3.26M | 5.78M | 7.36M | 13.90M | 23.75M |
| Total Debt | 640.00K | 1.56M | 2.51M | 878.00K | 1.46M | 1.48M |
| Total Liabilities | 3.17M | 3.02M | 3.75M | 3.57M | 3.19M | 5.52M |
| Stockholders Equity | 1.28M | 2.32M | 4.32M | 5.74M | 13.63M | 20.35M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -9.96M | -9.54M | -9.96M | -7.68M | -8.05M |
| Operating Cash Flow | 0.00 | -9.86M | -9.37M | -9.76M | -7.38M | -7.88M |
| Investing Cash Flow | 0.00 | 565.00K | 1.49M | 4.59M | -7.25M | -246.00K |
| Financing Cash Flow | 0.00 | 7.33M | 7.90M | 3.45M | -399.00K | 30.42M |
Inspira Technologies Oxy BHN Technical Analysis
Neutral
0.96
Price Trends
0.55
Negative
0.75
Negative
0.97
Negative
Market Momentum
-0.02
Negative
49.67
Neutral
60.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IINN, the sentiment is Neutral. The current price of 0.96 is above the 20-day moving average (MA) of 0.47, above the 50-day MA of 0.55, and below the 200-day MA of 0.97, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 49.67 is Neutral, neither overbought nor oversold. The STOCH value of 60.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IINN.
Inspira Technologies Oxy BHN Risk Analysis
Inspira Technologies Oxy BHN disclosed 70 risk factors in its most recent earnings report. Inspira Technologies Oxy BHN reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inspira Technologies Oxy BHN Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.56B | -13.83 | -21.49% | ― | 8.97% | -1024.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $165.14M | -4.35 | -32.46% | ― | 15.19% | -3.32% | |
46 Neutral | $5.31M | -0.21 | -279.58% | ― | 147.74% | 73.23% | |
45 Neutral | $63.36M | -1.67 | -82.79% | ― | 15.59% | 4.13% | |
44 Neutral | $37.07M | -4.85 | -91.54% | ― | -8.97% | 47.29% | |
41 Neutral | $22.14M | -2.02 | -279.06% | ― | ― | ― |
* Healthcare Sector Average
IINN
Inspira Technologies Oxy BHN
0.50
-0.07
-12.63%
CTSO
Cytosorbents
0.66
-0.43
-39.45%
LIVN
LivaNova
67.12
32.51
93.93%
XAIR
Beyond Air
0.54
-4.08
-88.24%
NNOX
Nano-X Imaging
2.85
-1.90
-40.00%
LUNG
Pulmonx
1.47
-3.05
-67.48%
Inspira Technologies Oxy BHN Corporate Events
Inspira Technologies Deploys AME System at Tier-1 U.S. Defense Customer
Apr 16, 2026
On April 16, 2026, Inspira Technologies announced it had completed the commercial delivery and customer acceptance of its Additively Manufactured Electronics (AME) system at a Tier-1 U.S. defense entity under a commercial agreement. The undisclose...
Inspira Technologies Calls May 6 Meeting to Rebrand as QTREX Ltd.
Apr 16, 2026
Inspira Technologies Oxy B.H.N. Ltd., an Israel-based medtech firm now pivoting toward quantum computing connectivity solutions, has convened an Extraordinary General Meeting of shareholders for May 6, 2026, in Ra’anana. Only holders of ordi...
Inspira Technologies Names Yoav Rozanovich Chief Business Officer
Apr 15, 2026
On April 13, 2026, Inspira Technologies Oxy B.H.N. Ltd. appointed 37-year-old Yoav Rozanovich as its Chief Business Officer, strengthening its senior leadership team. Rozanovich previously led global customer success at Nano Dimension Ltd. and ear...
Inspira Technologies Names New Chief Business Officer to Accelerate Quantum and AME Revenue
Apr 14, 2026
Inspira Technologies OXY B.H.N. Ltd., an Israel-based quantum connectivity and medical technology company listed on Nasdaq, develops hardware solutions that address critical physical constraints in scaling quantum computers, while also advancing r...
Inspira Technologies Begins AME Rollout With Top-Tier U.S. Tech Giant
Apr 13, 2026
On April 13, 2026, Inspira Technologies announced it had begun implementing its Additive Manufactured Electronics (AME) technology with a customer that ranks among the 10 largest U.S.-based companies, operating at the forefront of artificial intel...
Inspira Technologies Repositions as QTREX With Quantum Connectivity Push
Apr 6, 2026
On April 6, 2026, Israel‑based Inspira Technologies announced its entry into the quantum computing sector by repurposing its newly acquired additive manufactured electronics platform to develop 3D connectivity architectures for dilution cryo...
Inspira Technologies Closes $12.5 Million Acquisition of Nano Dimension’s AME Platform
Apr 6, 2026
On April 1, 2026, Inspira Technologies Oxy B.H.N. Ltd. signed an asset purchase agreement with Nano Dimension Technologies Ltd. to acquire the latter’s additive manufacturing electronics business and Fabrica business, with the transaction cl...
Inspira Technologies Ends ATM and SEPA Equity Facilities Ahead of Next Strategic Phase
Mar 31, 2026
On March 31, 2026, Inspira Technologies announced it had terminated its at-the-market sales agreement with A.G.P./Alliance Global Partners and its Standby Equity Purchase Agreement with YA II PN, Ltd., confirming there are no outstanding obligatio...
Inspira Technologies Ends Bio-View Deal, Strengthens Nasdaq Compliance as 2025 Loss Narrows Growth Path
Mar 26, 2026
Inspira Technologies reported full-year 2025 results on March 26, 2026, highlighting progress from clinical validation to early commercialization of its INSPIRA ART100 system, including first patient treatment in April 2025 at Westchester Medical ...
Inspira Technologies Creates Wholly Owned Subsidiary for Medical Business Reorganization
Mar 26, 2026
On March 26, 2026, Inspira Technologies Oxy B.H.N. Ltd. announced it has established a wholly owned subsidiary as part of an internal corporate reorganization. The company plans to transfer its existing medical business activities into this new en...
Inspira Technologies Amends Bio-View Debenture and Faces Nasdaq Market Value Deficiency Notice
Feb 25, 2026
Inspira Technologies Oxy B.H.N. Ltd., a commercial-stage Israeli MedTech company specializing in respiratory support systems and blood monitoring technologies, is leveraging its FDA-cleared INSPIRA ART100 and pipeline platforms such as INSPIRA ART...
Inspira Technologies Deploys ART100 at Top-Ranked New York Academic Medical Center
Feb 18, 2026
On February 17, 2026, Israel-based Inspira Technologies announced it had deployed its FDA-cleared INSPIRA ART100 cardiopulmonary support system at an additional leading U.S. academic medical center in New York. The hospital, ranked among the state...
Inspira Technologies Sets Up $2 Million At-the-Market Equity Program with A.G.P.
Feb 18, 2026
On February 17, 2026, Inspira Technologies Oxy B.H.N. Ltd. entered into a sales agreement with A.G.P./Alliance Global Partners that enables the company to issue and sell up to $2,015,985 of its ordinary shares from time to time through an at-the-m...
Inspira Technologies Faces Nasdaq Minimum Bid Price Deficiency, Retains Listing Through Compliance Window
Feb 12, 2026
Inspira Technologies OXY B.H.N. Ltd., a commercial-stage MedTech company, develops advanced respiratory support systems and blood monitoring technologies, including the FDA-cleared INSPIRA ART100 and its next-generation INSPIRA ART500 platform. Th...
Inspira Technologies Wins Clalit HMO Vendor Status, Clearing Path for ART100 Rollout
Feb 9, 2026
Inspira Technologies announced on February 9, 2026, that it has secured vendor approval from Clalit Health Services, the world’s second-largest integrated HMO with about 4.9 million members, enabling immediate procurement and deployment of i...
Inspira Technologies Raises $4.75 Million in At-the-Market Offering and Reprices Warrants
Feb 6, 2026
On February 5, 2026, Inspira Technologies Oxy B.H.N. entered into a definitive agreement with a single healthcare-focused institutional investor for a $4.75 million capital raise via a registered direct offering and concurrent private placement pr...
Inspira Technologies Validates Standalone HYLA Blood Sensor, Targeting $50 Billion Heart-Lung Surgery Market
Feb 3, 2026
On February 3, 2026, Inspira Technologies announced it has successfully validated its next-generation standalone HYLA blood sensor system in advanced blood labs, demonstrating 94.2% accuracy in continuous optical measurement of pCO₂ at a lev...
Inspira Technologies’ ART100 Completes Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center
Jan 29, 2026
On January 29, 2026, Inspira Technologies announced that its FDA-cleared INSPIRA ART100 system has completed full clinical evaluation and progressed into a budgeted procurement execution process at a leading U.S. academic medical center ranked amo...
Inspira Technologies Nears Final Government Approval for $49.5 Million in Purchase Orders
Jan 21, 2026
On January 21, 2026, Inspira Technologies announced that two previously disclosed binding purchase orders worth $22.5 million and $27 million, first reported on July 2 and August 19, 2025, have progressed to the final budgetary validation and fund...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.